Product Description
Verapamil is used to treat high blood pressure and to control angina (chest pain). The immediate-release tablets are also used alone or with other medications to prevent and treat irregular heartbeats. Verapamil is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard.
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Sweden, United States
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Coronary Disease|Panic Disorder|Type 1 Diabetes
Phase 1: Cardiomyopathy, Hypertrophic|Chronic Obstructive Pulmonary Disease|Healthy Volunteers|Tachycardia, Paroxysmal|Tachycardia, Supraventricular|Tachycardia, Ventricular
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06118684 |
EP395-004 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2024-01-02 |
2024-02-29 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06483789 |
HB-PD-002 | P2 |
Recruiting |
Panic Disorder |
2026-01-01 |
12% |
2024-12-20 |
Primary Endpoints|Start Date|Treatments|Trial Status |
2020-004966-20 |
Image-VER-A-T1D | P2 |
Active, not recruiting |
Type 1 Diabetes |
2023-08-05 |
2025-05-06 |
Treatments |
|
ACTRN12625000895482 |
ACTRN12625000895482 | P1 |
Not yet recruiting |
Tachycardia, Paroxysmal|Tachycardia, Ventricular|Tachycardia, Supraventricular |
2026-04-01 |
2025-08-22 |
Treatments |
|
ACTRN12625000894493 |
ACTRN12625000894493 | P1 |
Not yet recruiting |
Tachycardia, Supraventricular|Tachycardia, Ventricular|Tachycardia, Paroxysmal |
2026-04-01 |
2025-08-22 |
Treatments |
|
NCT06354556 |
HRS-1893-102 | P1 |
Completed |
Cardiomyopathy, Hypertrophic |
2024-05-20 |
12% |
2024-06-07 |
|
CTR20201327 |
CTR20201327 | P2 |
Recruiting |
Coronary Disease |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT06916897 |
EDG-5506-102 | P1 |
Completed |
Healthy Volunteers |
2025-02-22 |
2025-04-09 |
Primary Endpoints|Treatments |
|
CTR20240764 |
CTR20240764 | P1 |
Completed |
Healthy Volunteers |
2024-05-20 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06031454 |
RAY1216-23-05 | P1 |
Completed |
Healthy Volunteers |
2023-11-01 |
50% |
2024-04-17 |
Primary Endpoints |